Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 19NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 9Head & Neck 8Gastrointestinal 8Thoracic 5Sarcoma 5Gynecologic 5Endocrine 5CNS 3Breast 3Plasma cell 2Other solid neoplasm 2Other hematologic neoplasm 2NET 1Lymphoid 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Oligodendroglioma 1Mesothelioma 1Medulloblastoma 1Gliosarcoma 1Glioblastoma 1Familial ependymoma 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1

Interventions

Radiotherapy 63Temozolomide 59Magnetic Resonance Spectroscopy 46Carboplatin 40Cyclophosphamide 39Vincristine 35Specimen Handling 28Etoposide 26Cisplatin 26Radiation 22Chemotherapy, Adjuvant 22Filgrastim 20Bevacizumab 20Doxorubicin 18Peripheral Blood Stem Cell Transplantation 17Biopsy 17Vorinostat 16Surgical Procedures, Operative 14Melphalan 13Immunoglobulin G 13Disulfides 13Radiotherapy, Conformal 12Isotretinoin 12Erlotinib Hydrochloride 12X-Rays 11Nivolumab 11Irinotecan 11Carmustine 11aldesleukin 10Topotecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Fluorodeoxyglucose F18 × CNS × Clear all
NCT06503146 2026-05-19

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
320 enrolled
CNSEndocrineGastrointestinalGenitourinaryGynecologicOther solid neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Ovarian Neoplasms, Paraganglioma, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

NCT00662506 2023-06-06

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

National Cancer Institute (NCI)

Phase 1/2 Completed
46 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT00381797 2017-11-28

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

National Cancer Institute (NCI)

Phase 2 Completed
97 enrolled 35 charts
CNS

Familial ependymoma, Medulloblastoma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡